Figure 1.
Patient selection. FHCRC, Fred Hutchinson Cancer Research Center; JCAR014, investigational CD8+:CD4+ 1:1 defined-composition CD19-targeted CAR T cells; OHSU, Oregon Health and Science University. *Dose dense cohort, planned second infusion of CAR T cells 10-21 days after the first infusion without additional lymphodepletion.

Patient selection. FHCRC, Fred Hutchinson Cancer Research Center; JCAR014, investigational CD8+:CD4+ 1:1 defined-composition CD19-targeted CAR T cells; OHSU, Oregon Health and Science University. *Dose dense cohort, planned second infusion of CAR T cells 10-21 days after the first infusion without additional lymphodepletion.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal